INMB

Inmune Bio, Inc. INMB

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,879 of 2,925

Why it scores 9Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Top Institutional Holders

as of Q2 2026
$7.09M total
VANGUARD CAPITAL MANAGEMENT LLC
$1.15M+2.8%
AQR CAPITAL MANAGEMENT LLC
$1.08M+145.0%
BlackRock, Inc.
$507.9K-73.9%
RAYMOND JAMES FINANCIAL INC
$347.2K+4.8%
GEODE CAPITAL MANAGEMENT, LLC
$310.3K-61.6%
GOLDMAN SACHS GROUP INC
$301.9K-20.0%
MILLENNIUM MANAGEMENT LLC
$260.1KNew
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$258.3K-18.5%
JANE STREET GROUP, LLC
$218.8K+163.5%
UBS Group AG
$180.0K-56.4%
Westside Investment Management, Inc.
$176.5K0.0%
CITADEL ADVISORS LLC
$173.2KNew
VANGUARD FIDUCIARY TRUST CO
$170.8K-14.9%
STATE STREET CORP
$152.2K-67.9%
HRT FINANCIAL LP
$137.0KNew
IEQ CAPITAL, LLC
$134.3K+235.4%
GSA CAPITAL PARTNERS LLP
$134.0KNew
Virtu Financial LLC
$123.0KNew
Laird Norton Wetherby Trust Company, LLC
$84.8K+4.0%
Focus Partners Advisor Solutions, LLC
$71.0K+1.2%
PNC FINANCIAL SERVICES GROUP, INC.
$69.5K+6.3%
Qube Research & Technologies Ltd
$66.5KNew
Mariner, LLC
$65.7K+111.7%
NORTHERN TRUST CORP
$61.4K-79.6%
XTX Topco Ltd
$57.8K+17.0%
See all 83 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/INMB

Earnings Per Share

13fpro.ai/company/INMB

Loading ratio trend…

INMB key financials by period

Reported revenue, net income and operating margin by fiscal year, from Inmune Bio, Inc.'s annual filings on SEC EDGAR.

Inmune Bio, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$50.0K$-45.9M—
FY 2024$14.0K$-42.1M—
FY 2023$155.0K$-30.0M—
FY 2022$374.0K$-27.3M—
FY 2021$181.0K$-30.3M—
FY 2020$11.0K$-12.1M—
Source: INMB filings on SEC EDGAR →

INMB insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Inmune Bio, Inc. (INMB): stock profile, AI score and financials

Inmune Bio, Inc. (INMB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INMB at 9.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,879 of 2,925 stocks — the bottom half of the AI-ranked universe. Top institutional holders of INMB by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, AQR CAPITAL MANAGEMENT, BlackRock, based on the most recent SEC filings. INMB trades on the Nasdaq exchange and files with the SEC under CIK 1711754. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INMB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inmune Bio, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1711754 →